“Maintenance of Response With Guselkumab for up to 3 Years’ Treatment in the Phase 3 VOYAGE 1 Trial of Patients With Plaque Psoriasis”, J of Skin, vol. 2, p. S90, Dec. 2018, doi: 10.25251/skin.2.supp.91.